At a glance
- Originator Roche
- Developer Nonindustrial source; Roche
- Class Obesity therapies
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 13 Nov 1995 Discontinued-I for Obesity in Switzerland (Unknown route)